Chiral Announces Arbor Acquisition
Chiral Technologies Inc. has announced the acquisition of Arbor Biosciences.
Chiral Technologies Inc. (Pennsylvania, USA) has announced the acquisition of Arbor Biosciences (Michigan, USA).
Founded in 2006 by University of Michigan Prof. Erdogan Gulari and Dr. Jean-Marie Rouillard, Arbor Biosciences has evolved from producing custom DNA microarrays to generating oligonucleotide pools using proprietary massively parallel DNA synthesis technology.
“This is a very exciting time as we are moving Arbor Biosciences to the next level,” stated Jean-Marie Rouillard, CSO and co-founder at Arbor Biosciences “The additional investments by Chiral will help accelerate our growth and deliver innovative, cost-effective solutions to our clients in the biotechnology and life sciences markets faster than previously planned. It will also open up access to new markets.”
The company primarily produce targeted sequencing panels, which are complemented by their services division. Arbor recently expanded into synthetic biology with a cellâfree expression system using linear DNA as a template for rapid protein expression.
“As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth,” said Joseph Barendt, President of Chiral Technologies, Inc.
Arbor Biosciences will continue to operate at its current location in Ann Arbor as a wholly owned subsidiary of Daicel Corporation and managed by Chiral Technologies, Inc. The entire Arbor Biosciences team will remain in place, including co-founders Gulari and Rouillard.
For more information, please visit: www.chiraltech.com or www.arborbiosci.com
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ion used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
